Drug Shortage Report for TEVA-IRBESARTAN
Report ID | 92171 |
Drug Identification Number | 02316390 |
Brand name | TEVA-IRBESARTAN |
Common or Proper name | IRBESARTAN |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | IRBESARTAN |
Strength(s) | 75MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | C09CA |
ATC description | ANGIOTENSIN II ANTAGONISTS, PLAIN |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-08-22 |
Estimated end date | 2021-07-31 |
Actual end date | 2021-05-05 |
Shortage status | Resolved |
Updated date | 2021-05-06 |
Company comments | Will continue to allocate until regular supply can be restored (TBD) Allocating 100% of Teva market share from July to August. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v14 | 2020-02-07 | English | Compare |
v13 | 2020-01-30 | French | Compare |
v12 | 2020-01-30 | English | Compare |
v11 | 2019-12-05 | French | Compare |
v10 | 2019-12-05 | English | Compare |
v9 | 2019-11-28 | French | Compare |
v8 | 2019-11-28 | English | Compare |
v7 | 2019-11-28 | French | Compare |
v6 | 2019-11-28 | English | Compare |
v5 | 2019-09-26 | French | Compare |
v4 | 2019-09-26 | English | Compare |
v3 | 2019-08-23 | English | Compare |
v2 | 2019-08-22 | French | Compare |
v1 | 2019-08-22 | English | Compare |